Will we-the-quails unite to lift the net or wither away the gains made in AIDS response? By SHOBHA SHUKLA, BOBBY RAMAKANT ...

Participants who initiated long-acting cabotegravir-rilpivirine had a high rate of adherence and virologic suppression, with ...

Experts have proposed new treatment modes for older people with HIV. The new treatment does not cause the health-threatening ...

WHO recommends twice-yearly injectable lenacapavir for HIV prevention, expanding PrEP options for key populations.

A BREAKTHROUGH HIV drug that only needs to be injected twice a year to offer near-total protection from the virus and ...

For more than two decades, the global community has united to fight the HIV pandemic, achieving remarkable progress. New HIV transmissions and AIDS-related deaths have dropped significantly, and ...

A new injectable drug known as lenacapavir could change how millions of people across the world and Africa in particular access HIV protective drugs, which historically have hard to come by.

The investigational oral pre-exposure prophylaxis (PrEP) agent MK-8527 showed a similar, well-tolerated safety profile to placebo, with dose-proportional pharmacokinetics, among adults with a low ...

Newsday Zimbabwe HEALTH and Child Care minister Douglas Mombeshora has reaffirmed the country’s commitment to advancing HIV research, treatment and global collaboration. He said this during the ...

As borders tighten, Global South citizens say they are being locked out of high-level talks that impact them the most.

WHO endorses biannual injectable Lenacapavir for HIV prevention. This long-acting PrEP offers hope for high-risk groups and ...